G - Physics – 01 – N
Patent
G - Physics
01
N
G01N 33/574 (2006.01) A61K 39/395 (2006.01) C12Q 1/68 (2006.01)
Patent
CA 2677108
The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
La présente invention concerne l'utilisation de faible niveau de HER3 comme critère de sélection pour traiter des patients avec un inhibiteur de HER tel que le pertuzumab. Elle décrit également l'utilisation d'un rapport HER2:HER3 élevé en tant que critère de sélection pour traiter des patients souffrant de cancer, tels que des patientes souffrant de cancer ovarien, avec un inhibiteur de HER tel que le pertuzumab. De plus, l'invention décrit l'utilisation de niveau élevé de HER3 en tant que critère de sélection pour traiter les patients souffrant de cancer avec un agent chimiothérapeutique, par exemple, la gemcitabine.
Amler Lukas C.
Birkner Merrill
Lin Chin-Yu
Moecks Joachim
Strauss Andreas
F. Hoffman-La Roche Ag
Genentech Inc.
Smart & Biggar
LandOfFree
Predicting response to a her inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Predicting response to a her inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Predicting response to a her inhibitor will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1380895